API | zoliflodacin

zoliflodacin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Zoliflodacin is an experimental antibiotic that is being studied for the treatment of infection with Neisseria gonorrhoeae (gonorrhea). It has a novel mechanism of action which involves inhibition of bacterial type II topoisomerases. It is being developed by Entasis Therapeutics and is in Phase III clinical trials. ^Wikipedia

Chemistry

SMILES: C[C@@H]1CN2[C@H]([C@H](C)O1)C3(Cc4cc5c(noc5c(F)c24)N6[C@@H](C)COC6=O)C(=O)NC(=O)NC3=O
InChIKey: ZSWMIFNWDQEXDT-ZESJGQACSA-N
Mol. Mass: 487.44
ALogP: 1.2 Partition coefficient
ChEMBL Molecule:
zoliflodacin

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

azd0914 | azd-0914 | etx-0914 | zoliflodacin

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Gonorrhea (Phase 3)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue